Introduction: Despite studies examining daptomycin non-susceptible (DNS) Staphylococcus aureus, examination of the stability and population profiles is limited. The objective was to evaluate the stability, population profiles, and daptomycin activity against DNS isolates. Methods: The stability of 12 consecutive clinical DNS strains was evaluated by minimum inhibitory concentration (MICs) and population analysis profiles before and after 5 days of serial passage. Two pairs of DNS S. aureus having the same daptomycin MIC but different daptomycin population profiles were evaluated via an in vitro pharmacokinetic/ pharmacodynamic (PK/PD) model of simulated endocardial vegetations for 96 h against daptomycin 6 and 10 mg/kg/day. The sequence of mprF was determined for these isolates before and after 96 h of daptomycin exposure in the in vitro PK/PD model. Results: Daptomycin MIC values were 2-4 mg/L (via Microscan) for the 12 clinical isolates; 9 were confirmed DNS and 3 were within 1 tube dilution of Microscan (daptomycin MIC 1 mg/L). All were stable to serial passage. There was variation in the isolates susceptibility to daptomycin on population analysis (daptomycin population AUC 14.01-26.85). The killing patterns of Electronic supplementary material The online version of this article (daptomycin 6 and 10 mg/kg/day differed between isolates with a left-shift and rightshift population profile to daptomycin. Two strains developed additional mprF mutations during daptomycin exposure in the in vitro PK/ PD model resulting in P314L, L826F, S337L and a novel Q326Stop mutation. Conclusions: The collection of DNS isolates was stable and displayed variation in susceptibility to daptomycin on population profile. Further research examining this clinical relevance is warranted.
INTRODUCTION
Daptomycin is a cyclic lipopeptide antibiotic with activity against Gram-positive organisms that received approval from the United States Food and Drug Administration in September, 2003 [1] . It is a concentration-dependent bactericidal antibiotic that acts by binding to and inserting into the bacterial cytoplasmic membrane resulting in rapid depolarization and deregulation of several cell functions such as DNA, RNA and protein synthesis [2] [3] [4] .
Daptomycin susceptibility in Staphylococcus aureus is defined as a minimum inhibitory concentration (MIC) of B1 mg/L and any strain with an MIC [1 mg/L is considered daptomycin non-susceptible (DNS) [5] .
The development of DNS in S. aureus laboratory studies, clinical trials, and postmarketing surveillance has been relatively low. Spontaneous mutagenesis in S. aureus for DNS appears at a rate of less than 10 10 [6] .
Staphylococcus aureus with DNS can be obtained via extended serial passage with increasing daptomycin concentrations and via chemical mutagenesis. An in vitro model evaluated standard vancomycin and daptomycin dosing regimens against 5 clinical strains of S. aureus that developed DNS in vivo [7] . The DNS could only be replicated in vitro in 1/5 of these strains and with vancomycin but not daptomycin exposure. Interestingly, the DNS in this S. aureus strain was unstable and reverted back to susceptible upon passage on antibiotic free media. Only 7 of 120 patients in the phase III trial for S. aureus bacteremia and infective endocarditis trial developed isolates with DNS [8] . Evaluation of 22,858 S. aureus isolated in North America from 2005 to 2010 revealed only 14 strains with a daptomycin MIC of C2 mg/L, and no trend indicating increasing MICs was noted [9] .
Daptomycin non-susceptibility in S. aureus does not appear to be an all or nothing phenomenon, but instead a series of incremental changes that increase the MIC [10] [11] [12] [13] [14] [15] . To date, four main genetic changes (mprF, yycG, rpoB/rpoC, dltABCD) have been associated with increased MIC and DNS in S. aureus. Mutations in or overexpression of the mprF gene is commonly found in both laboratory derived and clinical DNS isolates [11] [12] [13] [14] . Increased quantities of the MprF protein, a lysylphosphatidylglycerol synthase, is thought to contribute to DNS by affecting the composition of the cell membrane via translocation of positively charged phospholipids to the outer side of the cytoplasmic membrane and by lysinylation of membrane phosphatidylglycerol (PG) to generate lysyl-PG (LPG) thereby increasing positive surface charge [14] [15] [16] . Recently mutations in the phospholipid biosynthesis genes cardiolipin synthase (cls2) and CDP-diacylglycerol-glycerol-3-phosphate 3 phosphatidyltransferase (pgsA) have been found in clinical DNS strains [17] . Another altered protein sometimes found in DNS strains is YycG, which is one of two components of a response regulator system involved in the metabolism of the cytoplasmic membrane and cell wall [11] . The proteins RpoB and RpoC, which comprise the b and b 0 subunit of RNA polymerase, have also been found with amino acid substitutions in DNS S. aureus strains [11] .
Recently, a single nucleotide polymorphism in rpoB from a laboratory derived DNS S. aureus was associated with decreased negative surface charge, increased cell wall thickness, and both vancomycin and daptomycin heteroresistance [18] . Additionally, increased expression of the dltABCD operon increases D-alanylation of cell wall teichoic acids contributing to an increase in positive surface charge [13] . Recent work has also suggested membrane proteins may augment the bactericidal effects of daptomycin, and alteration or loss of these proteins may contribute to DNS [15] . It has also USA) was used for population analysis profiles (PAP).
Serial Passage
All isolates confirmed as DNS by our laboratory were passed on TSA five consecutive times.
Isolates with a daptomycin MIC remaining C2 mg/L (±1 tube dilution standard error) after 5 serial passages were defined as stable DNS S. aureus strains and isolates reverting back to a daptomycin MIC of \1 mg/L were defined as unstable DNS S. aureus strains.
Susceptibility Testing
The MICs of daptomycin obtained by Microscan and for the isolates obtained with each serial passage were confirmed by broth microdilution (BMD) using an inoculum of 10 6 CFU/milliliter (mL) in duplicate according to CLSI standard methods and by Etest according to the manufacturer's guidelines [5] . S. aureus ATCC 25923 was used as a control strain. After greater than 2 years of storage at -80°C the daptomycin MIC of all isolates was retested to assess the effect of storage on the stability of the MIC.
Molecular Biology
All strains were characterized for SCCmec type, Panton-Valentine Leukocidin (PVL) status, and agr function and group by previously described methods [27] [28] [29] [30] [31] . S. aureus isolates were evaluated by pulse field gel electrophoresis (PFGE) using SmaI-digested DNA, as described 
Daptomycin Population Susceptibility
Profiles Fifty microliters of a *10 8 CFU/mL suspension of each strain was plated onto MHA plates with calcium containing daptomycin (concentrations ranging from 0.5 to 6 mg/L) using an automatic spiral plating device (WASP; DW Scientific, West Yorkshire, UK). After 48 h of incubation at 37°C, colony counts were determined using an automated colony counter (Synoptics Limited, Frederick, MD, USA). The lower limit of detection for colony count was 2 log 10 CFU/mL. Curves were constructed by plotting colony counts (log 10 CFU/mL) versus concentration. Strain SA-684, previously determined to be stable to passage, was used as a control strain [15] . 
In Vitro Model Experiment

Simulated Endocardial Vegetations
Organism stocks were prepared by creating lawns on TSA plates and incubating at 37°C overnight. Organisms were swabbed from the growth plates into five mL test tubes of MHBII, Bactericidal activity (99.9% kill) was defined as a C3 log 10 CFU/g reduction in colony count from the initial inoculum, bacteriostatic activity was defined as a \3 log 10 CFU/g reduction in colony count from the initial inoculum, and inactive was defined as no observed reductions in initial inocula. The time to achieve a 99.9% reduction was determined by linear regression or visual inspection (if r 2 C 0.95). Susceptibility was performed on the 96 h sample by broth microdilution.
Pharmacokinetic Analysis
Pharmacokinetic samples were obtained in duplicate through the injection port of each model at 0 The mprF genes were amplified by PCR using previously described primers [12] . The products were sequenced in both directions by an automated dideoxy chain termination method by the Applied Genomics Technology
Center, Wayne State University. Nucleotide sequence analysis was performed with DS Gene 1.5 (Accelrys, Inc. San Diego, CA, USA).
Membrane Potential Measurements
Membrane potential was compared between The activity of daptomycin 10 mg/kg against the four tested isolates revealed a similar pattern as the daptomycin 6 mg/kg regimen.
Daptomycin 10 mg/kg was bactericidal at 4 and 8 h against the two left-shift profile isolates (R6003 and R6219) with slow regrowth occurring for both strains by 96 h (Fig. 2b) . In 
DISCUSSION
While the occurrence of DNS in S. aureus is relatively rare, there is still much room for discovery on mechanisms of resistance and optimal treatment. While multiple studies have examined both genetic and phenotypic changes found in both laboratory derived and clinical DNS S. aureus, limited work has examined the population profiles or stability of these strains. Additionally, to our knowledge no previous work has attempted to evaluate the relationship between daptomycin activity and the daptomycin PAPs of DNS S. aureus strains.
In the current study, we found all 12 of the clinical DNS S. aureus strains to be stable in nature as they did not revert to susceptible after serial passage on drug free agar. Previous work examining laboratory derived and clinical DNS S. aureus strains has revealed the occurrence of an unstable DNS S. aureus phenotype. A DNS S. aureus strain recovered previously from an in vitro PK/PD model reverted back to its susceptible state after serial passage on drug free agar [35] . Additionally, examination of the resistant subpopulations from a clinical isogenic daptomycin susceptible/DNS pair, SA-675 and SA-684, revealed that the resistant subpopulations were unstable [15] .
Additionally, we found the majority (11/12) of strains to be stable in daptomycin MIC values after over 2 years of storage at -80°C. A recent paper examining daptomycin susceptible S. aureus strains found an overall decrease in MIC values after storage when tested by Etest [36] . This is in contrast to our study in which all but one strain was stable on repeat testing over two years later. These differences may be due to the While our study is novel in examining a large collection of DNS S. aureus strains for stability and PAP, it does have limitations.
Firstly, due to the relative rarity of DNS S. aureus, our collection of examined isolates is small at 12 and we were only able to obtain a single daptomycin susceptible-DNS isogenic pair for comparison evaluation. We also used standard inocula (log 10 6 CFU/mL) for broth microdilution and Etest susceptibility testing per CLSI and manufacturer's instructions, 
